UroGen Pharma Ltd (URGN)
13.30
-0.25
(-1.84%)
USD |
NASDAQ |
May 31, 16:00
13.31
+0.01
(+0.08%)
After-Hours: 20:00
UroGen Pharma Total Liabilities (Quarterly): 240.71M for March 31, 2024
Total Liabilities (Quarterly) Chart
Historical Total Liabilities (Quarterly) Data
Date | Value |
---|---|
March 31, 2024 | 240.71M |
December 31, 2023 | 243.52M |
September 30, 2023 | 235.63M |
June 30, 2023 | 233.80M |
March 31, 2023 | 229.51M |
December 31, 2022 | 224.98M |
September 30, 2022 | 191.76M |
June 30, 2022 | 187.05M |
March 31, 2022 | 182.79M |
December 31, 2021 | 111.33M |
September 30, 2021 | 103.07M |
June 30, 2021 | 97.50M |
March 31, 2021 | 20.92M |
December 31, 2020 | 25.65M |
September 30, 2020 | 19.37M |
Date | Value |
---|---|
June 30, 2020 | 18.42M |
March 31, 2020 | 16.48M |
December 31, 2019 | 22.09M |
September 30, 2019 | 15.84M |
June 30, 2019 | 13.79M |
March 31, 2019 | 12.46M |
December 31, 2018 | 13.46M |
September 30, 2018 | 8.975M |
June 30, 2018 | 7.952M |
March 31, 2018 | 5.535M |
December 31, 2017 | 7.035M |
September 30, 2017 | 4.927M |
June 30, 2017 | 4.966M |
December 31, 2016 | 6.749M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
13.79M
Minimum
Jun 2019
243.52M
Maximum
Dec 2023
121.71M
Average
107.20M
Median
Total Liabilities (Quarterly) Benchmarks
Agenus Inc | 446.88M |
Exelixis Inc | 675.74M |
Geron Corp | 137.21M |
Protalix BioTherapeutics Inc | 60.04M |
InfuSystems Holdings Inc | 52.57M |
Total Liabilities (Quarterly) Related Metrics
Total Assets (Quarterly) | 200.57M |
Shareholders Equity (Quarterly) | -40.13M |
Debt to Equity Ratio | -2.432 |
Current Ratio | 7.47 |
Net Debt Paydown Yield | -0.00% |